Premium
Generic and therapeutic substitution: a viewpoint on achieving best practice in Europe
Author(s) -
Johnston Atholl,
Asmar Roland,
Dahlöf Björn,
Hill Kate,
Jones David Albert,
Jordan Jens,
Livingston Michael,
MacGregor Graham,
Sobanja Michael,
Stafylas Panagiotis,
Rosei Enrico Agabiti,
Zamorano José
Publication year - 2011
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.2011.03987.x
Subject(s) - biosimilar , health care , substitution (logic) , scope (computer science) , medicine , public economics , risk analysis (engineering) , actuarial science , business , economics , computer science , economic growth , programming language
Given the current financial climate there is an ever increasing need to substitute drug treatments to optimize\udexpenditure. A closer examination of the beliefs surrounding\udwhen substitution is appropriate led a group of European\udhealthcare experts to argue that in some cases these\udbeliefs may be unfounded and that guidelines are needed\udfor clinical practice